NL-OMON39546已完成不适用
A dose-ascending, parallel group, randomised, double-blind, placebo-controlled pilot phase followed by a parallel group, randomised, double-blind, placebo-controlled phase to compare the effect of intravenous MR30507/09, MR30365/07 and fentanyl on respiratory responses, and an assessment of naloxone reversal and naltrexone blockade on MR30507/09 and MR30365/07 in healthy subjects - MR30507/09 respiratory response pilot study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Written informed consent obtained.
- •2. Healthy male subjects aged 18 to 45 years inclusive.
- •3. Body weight ranging from 60 to 100 kg and a BMI >= 18 and <= 30
- •4. Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and ECG.
- •5. Male subjects must be willing to use contraception with their partners throughout the study and for 30 days after completion of the study and agree to inform the Investigator if their partner becomes pregnant during this time
- •6. Subject is deemed suitable by the Investigator for inclusion in the study.
排除标准
- •1. Any history of drug or alcohol abuse, or recreational drug use within 30 days prior to study drug administration.
- •2. Any history of conditions that might interfere with drug absorption, distribution, metabolism or excretion.
- •3. Use of opioid or opioid antagonist-containing medication in the past 90 days.
- •4. Any history of frequent nausea or vomiting regardless of etiology.
- •5. Any history of seizures or symptomatic head trauma.
- •6. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
- •7. In the Investigator*s opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.
- •8. History of asthma, COPD, or other bronchial or lung diseases.
- •9. History of regurgitation or difficulty of intubation.
- •10. A history of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalaemia, personal or family history of long QT syndrome, syncope, or family history of sudden death).
- •11. Abnormal cardiac conditions including QTc interval greater than 450 msec at screening or pre-dose.
- •12. Use of medication within five times the half-life or minimum 14 days for prescription medication or 7 days for over-the-counter preparations (including vitamins, herbal and/or mineral supplements), whichever is longer, before the first dose of study treatment and during the study.
- •13. Refusal to abstain from food 6 hours preceding and 8 hours following study drug administration and to abstain from caffeine or xanthine containing beverages entirely during each confinement.
- •14. Weekly alcohol intake exceeding the equivalent of 21 units/week.
- •15. Consumption of alcoholic beverages within 24 hours before study drug administration, and refusal to abstain from alcohol for at least 48 hours after study drug administration.
- •16. History of heavy smoking (more than 20 cigarettes a day) within 45 days of study drug administration and refusal to abstain from smoking while in the study unit.
- •17. Blood or blood products donated within 90 days prior to study drug administration or any time during the study, except as required by this protocol.
- •18. Abnormal result obtained from Allen*s circulation test.
- •19. Positive results of urine drug screen, alcohol test, HBsAg, Hepatitis C antibody, or HIV tests.
- •20. Known sensitivity to fentanyl, opioids, naloxone, natrexone, or related compounds.
研究者
相似试验
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AN INVESTIGATIONAL INTRANASAL CORTICOSTEROID COMPARED TO PLACEBO AND OPEN-LABEL FLUTICASONE PROPIONATE AQUEOUS NASAL SPRAY (FLIXONASE™) ADMINISTERED FOR 28 DAYS TO PATIENTS 4 to 11 YEARS OLD WITH PERENNIAL ALLERGIC RHINITIS - LENS Peds PAR StudyPerennial (persistant) Allergic RhinitisEUCTR2005-000006-32-SKIVAX RESEARCH, INC.830
进行中（未招募）
不适用
A clinical study to investigate the pharmacokinetics safety, and tolerability of a single dose of GSK2402968 in non-ambulant subjects with Duchenne muscular dystrophy (GSK Study Number DMD114118)Duchenne Muscular DystrophyEUCTR2010-024566-22-Outside-EU/EEAGlaxoSmithKline Research and Development LTD32
进行中（未招募）
1 期
A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subjects with Duchenne muscular dystrophy - N/ADuchenne Muscular DystrophyEUCTR2010-024566-22-FRGlaxoSmithKline Research and Development LTD32
进行中（未招募）
不适用
A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis. - N/AEUCTR2006-005585-40-CZV Organon120
进行中（未招募）
不适用
A study for the investigation of safety of different doses of IBP-9414 that are randomly assigned to preterm infantsPrevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 gramsEUCTR2015-004228-70-SEInfant Bacterial Therapeutics AB120